Klinikum Konstanz GmbH

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis6 trials
• Bronchiectasis2 trials
• Chronic kidney disease2 trials
• Ovarian cancer2 trials
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Heart failure1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Osteoarthritis1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 27 trials
• Phase 37 trials
• Phase 42 trials

Status

• Recruiting7 trials
• Active, not recruiting5 trials
• Completed3 trials
• Not yet recruiting2 trials

Lead sponsor

• Boehringer Ingelheim4 trials
• Novartis Pharmaceuticals2 trials
• AbbVie1 trial
• Aesculap AG1 trial
• AGO Study Group1 trial
• and 8 more

Running trials

• Recruiting

  Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

  NCT07830719· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and chronic PsA colonization

  2025-523009-14-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1

  NCT06955481· Aesculap AG· Source

  Contact: Gunnar Ochs, Prof.Dr.med

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

  NCT05846230· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

  NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source

• Active, not recruiting

  AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting

  NCT04413201· Phase 4· Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR· Source

• Recruiting

  Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

  NCT05009082· Phase 3· AGO Study Group· Source

• Recruiting

  The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

  NCT04803994· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Swiss GO Trial Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis2 recruiting
• Ovarian cancer2 recruiting
• Atrial fibrillation1 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Osteoarthritis1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source